Scientific Publications

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Publication TypeJournal Article
AuthorsGreulich, H., Chen TH, Feng W., Jänne PA, Alvarez JV, Zappaterra M., Bulmer SE, Frank DA, Hahn WC, Sellers WR, and Meyerson M.
AbstractSomatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described.
Year of Publication2005
JournalPLoS medicine
Volume2
Issue11
Pagese313
Date Published (YYYY/MM/DD)2005/11/01
ISSN Number1549-1277
DOI10.1371/journal.pmed.0020313
PubMedhttp://www.ncbi.nlm.nih.gov/pubmed/16187797?dopt=Abstract